NCT03651726View on ClinicalTrials.gov

A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Tourette Syndrome
Interventions
DRUG

THX-110 (dronabinol plus PEA)

2.5 mg dronabinol capsules and 400 mg PEA tablets

DRUG

Placebo

Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets

Trial Locations (2)

30625

Medizinische Hochschule Hannover, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Hanover

80336

LMU Klinikum der Universität München, Klinik für Psychiatrie und Psychotherapie, Munich

Sponsors

Lead Sponsor

SciSparc
All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

lead

SciSparc

INDUSTRY

NCT03651726 - A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome | Biotech Hunter | Biotech Hunter